SIT Pharma (hereafter “SIT Pharma”) is pleased to announce the acquisition of DINTOINA brand.
The product is indicated for generalized epilepsy control, excluding petit mal and partial seizures.
Additional clinical uses of the drug are related to the treatment of trigeminal neuralgia, and some forms of cardiac arrhythmia.
The acquisition of DINTOINA confirms our will to grow our Italian portfolio in CNS area with essential and well know products and to maintain and assure, to patients and HCP’s, the therapeutic continuity.
SIT Pharma is an Italian-based pharmaceutical group with presence in 70 countries which develops, produces and commercializes more than 75 branded pharmaceutical products, Medical Devices and Food supplements.
About SIT Pharma
SIT Pharma is a family-owned pharmaceutical company, based in Italy since 1927, and today is an international pharmaceutical group with almost 100 years of experience and a recent history of prestigious acquisitions and global expansion. SIT Pharma is a reliable preferred acquirer for pharma businesses choosing to divest their “mature,” “established” or “tail” off-patent branded medicines.
In its two Italian manufacturing plants, SIT Pharma continues the high-quality “Made in Italy” drug manufacturing and management, aspiring to breathe new life into medicines, investing in them to renew the lifecycle and give new stability and sustainability over the long-term.
